Law360 (November 18, 2019, 12:01 PM EST) -- The U.S. Supreme Court said Monday it won't review Martin Shkreli's securities fraud conviction, making it all but certain that the former hedge fund manager and pharmaceutical executive will serve the rest of his seven-year prison sentence.
The U.S. Supreme Court said Monday it won't review Martin Shkreli's securities fraud conviction. Shkreli, left, is seen here with his lawyer in June 2017. (AP) Shkreli, 36, was convicted in 2017 of manipulating the price of stock in Retrophin Inc., his then-biotech firm, and of defrauding investors in hedge funds he ran. The Second Circuit upheld his conviction in July, leading Shkreli to...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!